1 / 40

Hematology Review May 15 2009

Hematology Review May 15 2009. Hematology Review. Vignette tips Pictures Laboratories Tests Treatment. Anemia. Iron deficinecy Macrocytic B12,Folate,MDS Anemia of chronic diseases Hemolytic Autoimmune TTP/HUS Drug induced Hemoglobinopathies. Anemia. Iron deficiency.

dagmar
Download Presentation

Hematology Review May 15 2009

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Hematology ReviewMay 15 2009

  2. Hematology Review • Vignette tips • Pictures • Laboratories Tests • Treatment

  3. Anemia • Iron deficinecy • Macrocytic B12,Folate,MDS • Anemia of chronic diseases • Hemolytic • Autoimmune • TTP/HUS • Drug induced • Hemoglobinopathies

  4. Anemia • Iron deficiency

  5. Iron deficiency • Vignette tips • Pictures • Laboratories Tests • Low Iron • High IBC • Low Ferritin • Treatment • Give Iron • LOOK FOR SOURCE OF BLEEDING

  6. Iron deficiency

  7. Iron deficiency Low Iron High IBC Low Ferritin

  8. Macrocytic B12,Folate,MDS • Vignette tips • Pictures • Laboratories Tests • Treatment • Never answer folate alone as initial therapy • Look for associated disease

  9. Anemia • Autoimmune Hemolytic Anemia

  10. Anemia • Hemoglobinopathies

  11. Case 3

  12. Case 3

  13. Thrombocytopenia • ITP • HIV • TTP/HUS • HIT • Other drugs

  14. Thrombocytopenia • TTP

  15. HIT • Clinical diagnosis • Laboratory helps but does not always • When in doubt DTI

  16. Coagulopathies • Hemophilia • X linked disorder • Von Willebrand disease • Type I • Type II and IIn • Type III • Platelet function abnormalities • Aspirin

  17. Hemophilia

  18. Thrombophilias • Protein C and S • Antithrombin III • Prothrombin mutations • Factor V Leiden • Antiphospholipid syndrome

  19. Antiphospholipid syndrome • Acquired thrombophilic condition • Vascular thrombosis or recurrent pregnancy loss • Presence of Antibodies that recognize phospholipids or PL binding proteins.

  20. Sapporo Criteria

  21. Lupus anticoagulant testing

  22. Lupus anticoagulant testing

  23. ELISA

  24. Myeloproliferative disorder • P.Vera Jak2 • CML Imatinib,Desatinib, • ET • Myelofibrosis

  25. Myelodisplasia • Definition • Chromosomes • 5q Lenalidomide (Revlimid) • EpigeneticsDecitabine, 5 Azacytidine

  26. Drugs

  27. Laboaratory • Prolonged PT and PTT • MCV • Retic • Fe studies

  28. Blood Bank • Type and Crossmatch • Transfusion reactions

  29. Hematological malignancies • Acute leukemia • If DIC think APL/M3/Promyelocytic leukemia • If extramedulary manifestation think monocytic/monoblastic M4 M5 • If Auer rods call it AML • If no Auer Rods cannot call it AML or ALL

  30. Hematological malignanciesAcute leukemia

  31. Hematological malignanciesLymphoma • Low grade lymphomas • Indolent/No cure/watchfull wait is an option/Rituximab • CLL • Follicular • Intermediate • More aggressive, chemotherapy can cure/Rituximab • Diffuse large cell • Aggressive • Burkitt’s

  32. Hematological malignanciesLymphoma

  33. Hematological malignanciesMyeloma • Kidney • Bone • Amyloid • Anemia • Thalidomide, Revlimid, Bortezomib, Transplant • Biphosphonates • Osteonecrosis of the jaw

  34. DVT/PE • Hypercoagulable states • Except for APLS and possibly pregnancy recommendations rarely affect management • Do not ask for ATIII if pt on heparin or acute clot • Do not ask for Prot C or S if pt has acute clot or is on coumadin • Molecular studies FV Leiden or Prothrombin gene mutation can be done anytime • If low plt or recent hospitalization think HIT

  35. DVT/PE • Duration of anticoag (2008 ACCP guidelines) • Provoked • Provoking factor gone 3 months • Unprovoked (1st episode) • No less than 3 months, consider long term if no contraindications for AC • Unproked (2nd episode) • Lifelong

  36. DVT/PE • 2.1.1. For patients with DVT secondary to a transient (reversible) risk factor, we recommend treatment with a VKA for 3 months over treatment for shorter periods (Grade 1A). • 2.1.2. For patients with unprovoked DVT, we recommend treatment with a VKA for at least 3 months (Grade 1A). We recommend that after 3 months of anticoagulant therapy, all patients with unprovoked DVT should be evaluated for the risk-benefit ratio of long-term therapy (Grade 1C). For patients with a first unprovoked VTE that is a proximal DVT, and in whom risk factors for bleeding are absent and for whom good anticoagulant monitoring is achievable, we recommend long-term treatment (Grade 1A). Values and preferences: This recommendation attaches a relatively high value to prevention of recurrent VTE and a lower value to the burden of long-term anticoagulant therapy. • For patients with a second episode of unprovoked VTE, we recommend long-term treatment (Grade 1A). For patients with a first isolated distal DVT that is unprovoked, we suggest that 3 months of anticoagulant therapy is sufficient rather than indefinite therapy (Grade 2B). • 2.1.3. For patients with DVT and cancer, we recommend LMWH for the first 3 to 6 months of long-term anticoagulant therapy (Grade 1A). For these patients, we recommend subsequent anticoagulant therapy with VKA or LMWH indefinitely or until the cancer is resolved (also, see Section 2.4) [Grade 1C]. • 2.1.4. In patients who receive long-term anticoagulant treatment, the risk-benefit ratio of continuing such treatment should be reassessed in the individual patient at periodic intervals (Grade 1C)

  37. Filters • 1.13.1. For patients with DVT, we recommend against the routine use of a vena cava filter in addition to anticoagulants (Grade 1A). • 1.13.2. For patients with acute proximal DVT, if anticoagulant therapy is not possible because of the risk of bleeding, we recommend placement of an inferior vena cava (IVC) filter (Grade 1C). • 1.13.3. For patients with acute DVT who have an IVC filter inserted as an alternative to anticoagulation, we recommend that they should subsequently receive a conventional course of anticoagulant therapy if their risk of bleeding resolves (Grade 1C).

  38. Porphyrias * * *

More Related